The landscape of chronic disease management is being permanently altered by the "Biosimilar Wave" of the mid-2020s. In 2026, the US Biosimilars Market is seeing the full maturity of the adalimumab (Humira) market, which served as a "Stress Test" for the American healthcare system. With more than 10 competitors now available for this single molecule, list prices have dropped significantly, and...
0 Reacties
0 aandelen
266 Views
0 voorbeeld
Sponsor
×
Install Ework Face
Install our app for a better experience, faster access, and offline capabilities.